^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers

Excerpt:
Vandetanib induced tumor regression in PDX models with high expression of RET or EGFR.
DOI:
10.1002/ijc.29974